BioCryst Pharmaceuticals Statistics
Total Valuation
BCRX has a market cap or net worth of $1.98 billion. The enterprise value is $2.43 billion.
| Market Cap | 1.98B |
| Enterprise Value | 2.43B |
Important Dates
The last earnings date was Wednesday, November 4, 2026, before market open.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BCRX has 257.30 million shares outstanding. The number of shares has increased by 15.25% in one year.
| Current Share Class | 257.30M |
| Shares Outstanding | 257.30M |
| Shares Change (YoY) | +15.25% |
| Shares Change (QoQ) | +0.93% |
| Owned by Insiders (%) | 0.89% |
| Owned by Institutions (%) | 90.99% |
| Float | 224.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 10.93 |
| PS Ratio | 2.06 |
| Forward PS | 2.77 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 5.41 |
| P/OCF Ratio | 5.38 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.15, with an EV/FCF ratio of 6.65.
| EV / Earnings | n/a |
| EV / Sales | 2.53 |
| EV / EBITDA | 5.15 |
| EV / EBIT | 5.19 |
| EV / FCF | 6.65 |
Financial Position
The company has a current ratio of 2.71
| Current Ratio | 2.71 |
| Quick Ratio | 2.54 |
| Debt / Equity | n/a |
| Debt / EBITDA | 1.74 |
| Debt / FCF | 2.26 |
| Interest Coverage | 6.10 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 56.48% |
| Return on Invested Capital (ROIC) | 125.97% |
| Return on Capital Employed (ROCE) | 118.60% |
| Weighted Average Cost of Capital (WACC) | 7.15% |
| Revenue Per Employee | $2.21M |
| Profits Per Employee | -$826,795 |
| Employee Count | 435 |
| Asset Turnover | 1.85 |
| Inventory Turnover | 22.17 |
Taxes
In the past 12 months, BCRX has paid $4.92 million in taxes.
| Income Tax | 4.92M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.25% in the last 52 weeks. The beta is 0.51, so BCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | +7.25% |
| 50-Day Moving Average | 8.46 |
| 200-Day Moving Average | 8.78 |
| Relative Strength Index (RSI) | 40.82 |
| Average Volume (20 Days) | 5,922,530 |
Short Selling Information
The latest short interest is 26.60 million, so 10.34% of the outstanding shares have been sold short.
| Short Interest | 26.60M |
| Short Previous Month | 27.49M |
| Short % of Shares Out | 10.34% |
| Short % of Float | 11.87% |
| Short Ratio (days to cover) | 4.97 |
Income Statement
In the last 12 months, BCRX had revenue of $961.51 million and -$359.66 million in losses. Loss per share was -$1.49.
| Revenue | 961.51M |
| Gross Profit | 751.18M |
| Operating Income | 468.76M |
| Pretax Income | -354.73M |
| Net Income | -359.66M |
| EBITDA | 472.47M |
| EBIT | 468.76M |
| Loss Per Share | -$1.49 |
Balance Sheet
The company has $375.00 million in cash and $828.20 million in debt, with a net cash position of -$453.20 million or -$1.76 per share.
| Cash & Cash Equivalents | 375.00M |
| Total Debt | 828.20M |
| Net Cash | -453.20M |
| Net Cash Per Share | -$1.76 |
| Equity (Book Value) | -397.38M |
| Book Value Per Share | -1.55 |
| Working Capital | 335.32M |
Cash Flow
In the last 12 months, operating cash flow was $367.49 million and capital expenditures -$1.65 million, giving a free cash flow of $365.85 million.
| Operating Cash Flow | 367.49M |
| Capital Expenditures | -1.65M |
| Depreciation & Amortization | 3.71M |
| Net Borrowing | 173.34M |
| Free Cash Flow | 365.85M |
| FCF Per Share | $1.42 |
Margins
Gross margin is 78.12%, with operating and profit margins of 48.75% and -37.41%.
| Gross Margin | 78.12% |
| Operating Margin | 48.75% |
| Pretax Margin | -36.89% |
| Profit Margin | -37.41% |
| EBITDA Margin | 49.14% |
| EBIT Margin | 48.75% |
| FCF Margin | 38.05% |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -15.25% |
| Shareholder Yield | -15.25% |
| Earnings Yield | -19.42% |
| FCF Yield | 18.49% |
Analyst Forecast
The average price target for BCRX is $20.45, which is 165.93% higher than the current price. The consensus rating is "Buy".
| Price Target | $20.45 |
| Price Target Difference | 165.93% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | -1.73% |
| EPS Growth Forecast (3Y) | 25.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BCRX has an Altman Z-Score of 1.15 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.15 |
| Piotroski F-Score | 6 |